MX2024007894A - Fitusirán para su uso para mejorar el resultado comunicado por el paciente en pacientes con hemofilia. - Google Patents

Fitusirán para su uso para mejorar el resultado comunicado por el paciente en pacientes con hemofilia.

Info

Publication number
MX2024007894A
MX2024007894A MX2024007894A MX2024007894A MX2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A
Authority
MX
Mexico
Prior art keywords
hemophilia
patients
improve patient
fitusiran
patient reported
Prior art date
Application number
MX2024007894A
Other languages
English (en)
Spanish (es)
Inventor
Shauna Andersson
Pronabesh Dasmahapatra
Jose Bartelt-Hofer
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2024007894A publication Critical patent/MX2024007894A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024007894A 2021-12-22 2022-12-22 Fitusirán para su uso para mejorar el resultado comunicado por el paciente en pacientes con hemofilia. MX2024007894A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163293070P 2021-12-22 2021-12-22
US202263305550P 2022-02-01 2022-02-01
US202263335535P 2022-04-27 2022-04-27
US202263359717P 2022-07-08 2022-07-08
US202263382223P 2022-11-03 2022-11-03
US202263386489P 2022-12-07 2022-12-07
PCT/US2022/082213 WO2023122713A1 (en) 2021-12-22 2022-12-22 Fitusiran for use in improving patient-reported outcome in hemophilia patients

Publications (1)

Publication Number Publication Date
MX2024007894A true MX2024007894A (es) 2024-08-20

Family

ID=85227438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007894A MX2024007894A (es) 2021-12-22 2022-12-22 Fitusirán para su uso para mejorar el resultado comunicado por el paciente en pacientes con hemofilia.

Country Status (10)

Country Link
US (1) US20250064842A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452280A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500412A (cg-RX-API-DMAC7.html)
KR (1) KR20240138572A (cg-RX-API-DMAC7.html)
AU (1) AU2022419588A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243297A1 (cg-RX-API-DMAC7.html)
IL (1) IL313677A (cg-RX-API-DMAC7.html)
MX (1) MX2024007894A (cg-RX-API-DMAC7.html)
TW (1) TW202342065A (cg-RX-API-DMAC7.html)
WO (1) WO2023122713A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物
WO2022120291A1 (en) * 2020-12-06 2022-06-09 Genzyme Corporation Treatment of hemophilia with fitusiran

Also Published As

Publication number Publication date
JP2025500412A (ja) 2025-01-09
KR20240138572A (ko) 2024-09-20
AU2022419588A1 (en) 2024-08-01
WO2023122713A1 (en) 2023-06-29
US20250064842A1 (en) 2025-02-27
CA3243297A1 (en) 2023-06-29
TW202342065A (zh) 2023-11-01
EP4452280A1 (en) 2024-10-30
IL313677A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
MX2022012992A (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2017013432A2 (es) Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones
MX2016005574A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
CO6960552A2 (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
NI201500123A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
CR20170477A (es) Terapia de combinacin del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cncer
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX338447B (es) Tratamiento para diabetes en pacientes inapropirados para terapia con metformina.
MX2014001218A (es) Tratamiento de cancer de mama.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2023000703A2 (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida
CO2025003263A2 (es) Inhibidores de kif18a y usos de estos
MX386293B (es) Compuestos de aminoindano y su uso en el tratamiento del dolor.
CO2024014485A2 (es) Compuestos heterociclicos moduladores de bcl6 como degradadores dirigidos por ligando
MX2023000164A (es) Métodos y composiciones para tratar la hemofilia.